Evidence map›Paper›PMID 39463382›Full record

ArticleScientific reports2024

Development of a novel immunocompetent murine tumor model for urothelial carcinoma using in vivo electroporation.

Stefan Soleder, Nicolas Gengenbacher, Carolin Mogler, Markus Eckstein, Anja Runge, Maximilian C Kriegmair, Hellmut G Augustin

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Stefan SolederDivision of Vascular Oncology and Metastasis Research, German Cancer Research Center Heidelberg (DKFZ), Heidelberg, Germany. stefan.soleder@gmail.com.
Nicolas GengenbacherDivision of Vascular Oncology and Metastasis Research, German Cancer Research Center Heidelberg (DKFZ), Heidelberg, Germany.
Carolin MoglerDepartment of Pathology, Technical University of Munich, Munich, Germany.
Markus EcksteinInstitute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen- Nürnberg, Erlangen, Germany.
Anja RungeDivision of Vascular Oncology and Metastasis Research, German Cancer Research Center Heidelberg (DKFZ), Heidelberg, Germany.
Maximilian C KriegmairDivision of Vascular Oncology and Metastasis Research, German Cancer Research Center Heidelberg (DKFZ), Heidelberg, Germany.
Hellmut G AugustinDivision of Vascular Oncology and Metastasis Research, German Cancer Research Center Heidelberg (DKFZ), Heidelberg, Germany. augustin@angioscience.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A lack of advanced preclinical mouse tumor models impedes the progress in urothelial carcinoma research. We present here a novel fast, robust, reliable, and highly reproducible model for the genetic induction of bladder cancer in immunocompetent mice. Different sets of oncogenic transposons (Cmyc, Kras) and Cre drivers were transfected into the murine bladder wall of two different genetic backgrounds (Trp53

Indexed as

Disease Models, AnimalElectroporationUrinary Bladder NeoplasmsAnimalsCarcinoma, Transitional CellFemaleMice

Identifiers

PMID39463382
PMCPMC11514157

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.